Fusion Pharmaceuticals Raises $105 Million In Oversubscribed Series B Financing

Ontario Industry Updates
Written By Guest User

Fusion Pharmaceuticals announced the completion of a $105 million Series B financing led by Varian and new investor OrbiMed. 

Click here to read more

Guest User
Previous

XPan Wins FACIT Falcons’ Fortunes Pitch Competition
Next

AceAge Wins Innovation in Aging Pitch Competition